Drug intelligence / Profile preview

YBioA4003

Development stage: Preclinical
Lead developer: Yerlika Biopharma

Overview

YBioA4003 is a cell line-derived biologic currently in preclinical development by Yerlika Biopharma for the treatment of rare blood diseases. As of early 2024, the program is in the cell line and process development stage, with a regulatory dossier submission anticipated in 2028 and potential market approval in 2029. While the specific molecular target and mechanism of action have not been disclosed, the developer's focus on biosimilars suggests it may be a biosimilar candidate for an existing biologic therapy in the hematology space.

Beyond the preview

Go deeper on YBioA4003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YBioA4003.

Explore the full profile